 CAMBRIDGE, Mass. HONG KONG SHANGHAI FLORHAM PARK, N.J.--BUSINESS WIRE--Epizyme, Inc. Epizyme Nasdaq: EPZM, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, and HUTCHMED China Limited HUTCHMED NasdaqAIM:HCM; HKEX:13, today announce a collaboration to research, develop, manufacture and commercialize TAZVERIK in Greater China, including mainland China, Hong Kong, Macau and Taiwan the Territory. TAZVERIK 